89Zirconium-labelled girentuximab (89Zr-TLX250) PET in Urothelial Cancer Patients (ZiPUP): protocol for a phase I trial of a novel staging modality for urothelial carcinoma
Mohammed Al-Zubaidi,
Elizabeth Liow,
Dickon Hayne,
Andrew D Redfern,
Tom Ferguson,
Steve McCombie,
Pravin Viswambaram,
Nat Lenzo,
Richard Gauci
Affiliations
Mohammed Al-Zubaidi
Department of Urology, Fiona Stanley Hospital, Murdoch, Western Australia, Australia
Elizabeth Liow
Personalised Oncology Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia
Dickon Hayne
Department of Urology, Fiona Stanley Hospital, Murdoch, Western Australia, Australia
Andrew D Redfern
Department of Medical Oncology, Fiona Stanley Hospital, Perth, Australia
Tom Ferguson
Department of Medical Oncology, Fiona Stanley Hospital, Perth, Australia
Steve McCombie
Department of Urology, Fiona Stanley Hospital, Murdoch, Western Australia, Australia
Pravin Viswambaram
Urology, Fiona Stanley Hospital, Murdoch, Western Australia, Australia
Nat Lenzo
Nuclear Medicine, Fiona Stanley Hospital, Murdoch, Western Australia, Australia
Richard Gauci
Nuclear Medicine, Fiona Stanley Hospital, Murdoch, Western Australia, Australia